Improved initial burst of estradiol organogel as long-term in situ drug delivery implant: Formulation, in vitro and in vivo characterization

Drug Development and Industrial Pharmacy

Volumn 38, Issue 5, 2012, Pages 550-556

  Yang, Yang ^a   Xu, Lu ^a   Gao, Yanan ^a   Wang, Qifang ^a   Che, Xin ^a   Li, Sanming ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Estradiol; formulation optimization; in situ organogel; in vitro release; in vivo release

Indexed keywords

1 METHYL 2 PYRROLIDINONE; ESTRADIOL; ESTRADIOL ORGANOGEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORROSION; DIFFUSION; DRUG FORMULATION; FEMALE; FLOW MEASUREMENT; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG IMPLANTS; ESTRADIOL; GELS; HUMANS; LYSINE; PYRROLIDINONES; TIME FACTORS;

EID: 84859300796     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.665928     Document Type: Article

References (27)

1. Azuma K, Inoue S. (2004). [Hormone replacement therapy]. Clin Calcium, 14:153-164.
2. Farris C Jr. (2004). Women's health and hormone replacement therapy. South Med J, 97:1143.
3. Kanaoka Y, Honda K, Ishiko O, Hirai K, Ogita S. (2003). Long-term effects of hormone replacement therapy on bone mineral density in girls oophorectomized in adolescence. Gynecol Obstet Invest, 55:168-172. (Pubitemid 36928637)
4. Levine JP. (2003). Long-term estrogen and hormone replacement therapy for the prevention and treatment of osteoporosis. Curr Womens Health Rep, 3:181-186.
5. Steel SA, Albertazzi P, Howarth EM, Purdie DW. (2003). Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis. Climacteric, 6:96-103. (Pubitemid 36714081)
6. Deady J. (2004). Clinical monograph: hormone replacement therapy. J Manag Care Pharm, 10:33-47.
7. Yoo JW, Lee CH. (2006). Drug delivery systems for hormone therapy. J Control Release, 112:1-14.
8. Upadhyay KK, Tiwari C, Khopade AJ, Bohidar HB, Jain SK. (2007). Sorbitan ester organogels for transdermal delivery of sumatriptan. Drug Dev Ind Pharm, 33:617-625. (Pubitemid 47035888)
9. Kang L, Liu XY, Sawant PD, Ho PC, Chan YW, Chan SY. (2005). SMGA gels for the skin permeation of haloperidol. J Control Release, 106:88-98. (Pubitemid 41140084)
10. Lim PF, Liu XY, Kang L, Ho PC, Chan YW, Chan SY. (2006). Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol. Int J Pharm, 311:157-164.
11. Moniruzzaman M, Sundararajan PR. (2005). Low molecular weight organogels based on long-chain carbamates. Langmuir, 21:3802-3807. (Pubitemid 40654582)
12. Pénzes T, Blazsó G, Aigner Z, Falkay G, Eros I. (2005). Topical absorption of piroxicam from organogels-in vitro and in vivo correlations. Int J Pharm, 298:47-54. (Pubitemid 40834314)
13. Vintiloiu A, Lafleur M, Bastiat G, Leroux JC. (2008). In situ-forming oleogel implant for rivastigmine delivery. Pharm Res, 25:845-852. (Pubitemid 351661832)
14. Vintiloiu A, Leroux JC. (2008). Organogels and their use in drug delivery - a review. J Control Release, 125:179-192.
15. Ruiz MA, Clares B, Morales ME, Gallardo V. (2008). Vesicular lipidic systems, liposomes, PLO, and liposomes-PLO: characterization by electronic transmission microscopy. Drug Dev Ind Pharm, 34:1269-1276.
16. Wang K, Jia Q, Han F, Liu H, Li S. (2010). Self-assembled l-alanine derivative organogel as in situ drug delivery implant: characterization, biodegradability, and biocompatibility. Drug Dev Ind Pharm, 36:1511-1521.
17. Couffin-Hoarau AC, Motulsky A, Delmas P, Leroux JC. (2004). In situ-forming pharmaceutical organogels based on the selfassembly of l-alanine derivatives. Pharm Res, 21:454-457. (Pubitemid 38338981)
18. Luo X, Liu B, Liang Y. (2001). Self-assembled organogels formed by mono-chain l-alanine derivatives. Chem Commun (Camb), 7:1556-1557. (Pubitemid 32807992)
19. Wang Y, Tang L, Yu J. (2008). Investigation on the assembled structure-property correlation of supramolecular hydrogel formed from low-molecular-weight gelator. J Colloid Interface Sci, 319:357-364.
20. George M, Snyder SL, Terech P, Glinka CJ, Weiss RG. (2003). N-alkyl perfluoroalkanamides as low molecular-mass organogelators. J Am Chem Soc, 125:10275-10283. (Pubitemid 37022239)
21. Nahata T, Saini TR. (2008). Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine. J Microencapsul, 25:426-433.
22. Miyazaki Y, Yakou S, Yanagawa F, Takayama K. (2008). Evaluation and optimization of preparative variables for controlled-release floatable microspheres prepared by poor solvent addition method. Drug Dev Ind Pharm, 34:1238-1245.
23. De Smedt SC, Dekeyser P, Ribitsch V, Lauwers A, Demeester J. (1993). Viscoelastic and transient network properties of hyaluronic acid as a function of the concentration. Biorheology, 30:31-41. (Pubitemid 23181139)
24. Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv, 60:110-111.
25. Tsai YH, Fu LT, Huang CT, Chang JS, Huang YB, Wu PC. (2011). Formulation optimization of estradiol microemulsion using response surface methodology. J Pharm Sci, 100:4383-4389.
26. Dabhi M, Gohel M, Parikh R, Sheth N, Nagori S. (2011). Formulation development of ambroxol hydrochloride soft gel with application of statistical experimental design and response surface methodology. PDA J Pharm Sci Technol, 65:20-31.
27. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. (2007). Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release, 119:77-85. (Pubitemid 46561546)